Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
137.57
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
57
58
Next >
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
May 21, 2024
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
Via
Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
May 21, 2024
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
Via
Benzinga
Topics
ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
May 21, 2024
Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year.
Via
InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
May 21, 2024
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide.
Via
Benzinga
Is Novo Nordisk Stock a Millionaire Maker?
May 18, 2024
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Via
The Motley Fool
Smart Money Is Betting Big In NVO Options
May 17, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
May 16, 2024
Via
Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
May 21, 2024
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now.
Via
InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
May 21, 2024
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1...
Via
Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
May 20, 2024
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections.
Via
InvestorPlace
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
May 20, 2024
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month.
Via
Benzinga
Should Quality Investors Include NYSE:NVO in Their Portfolio?
May 16, 2024
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
Via
Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
May 14, 2024
Via
Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
May 20, 2024
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This...
Via
Benzinga
Magnificent Seven? Just Two Members Meet This Earnings Criteria
May 20, 2024
These megacaps meet triple-25% growth standards.
Via
Investor's Business Daily
Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green
May 18, 2024
The market has flashed a green signal to investors.
Via
Investor's Business Daily
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
May 17, 2024
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.
Via
Benzinga
Topics
ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
May 17, 2024
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 17, 2024
Via
Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
May 17, 2024
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via
News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
May 17, 2024
Could Amgen be the next stock to soar due to a GLP-1 drug?
Via
The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
May 16, 2024
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
May 15, 2024
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and...
Via
Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
May 15, 2024
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
Via
The Motley Fool
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
May 15, 2024
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal...
Via
Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
May 15, 2024
This company is serious about maintaining its leadership.
Via
The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
May 14, 2024
Both of these businesses are finding traction in a pair of major markets.
Via
The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
May 14, 2024
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
57
58
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.